In this regard, the big challenge of understanding the interaction of different members and isoforms of the p38MAPK signaling pathway and their integration with other signals from MAPK pathways, oncogenic and tumor suppressive mediators (such as p53), comes with the potential reward of a broad repertoire of therapeutic targets. Here, TP53 is linked to neoplasm.